Phosphoinositide lipids play a key role in cellular physiology, participating in a wide array of cellular processes. Consequently, mutation of phosphoinositide-metabolizing enzymes is responsible for a growing number of diseases in humans. Two related disorders, oculocerebrorenal syndrome of Lowe (OCRL) and Dent-2 disease, are caused by mutation of the inositol 5-phosphatase OCRL1. Here, we review recent advances in our understanding of OCRL1 function. OCRL1 appears to regulate many processes within the cell, most of which depend upon coordination of membrane dynamics with remodeling of the actin cytoskeleton. Recently developed animal models have managed to recapitulate features of Lowe syndrome and Dent-2 disease, and revealed new insights into the underlying mechanisms of these disorders. The continued use of both cell-based approaches and animal models will be key to fully unraveling OCRL1 function, how its loss leads to disease and, importantly, the development of therapeutics to treat patients.
Mutation of the inositol 5-phophatase OCRL1 causes two disorders in humans, namely Lowe syndrome and Dent-2 disease. Significant progress in understanding the functions of OCRL1 has been made in recent years, indicating a role for the protein in diverse cellular processes. Moreover, the recent emergence of animal models has provided new insights into the mechanisms by which loss of OCRL1 leads to disease. Here, we review recent advances in understanding OCRL1 made at both the cellular and organismal level.